Inclusion Criteria:

PROCUREMENT:

1. Any patient, at least 18 years old regardless of sex with a diagnosis of Hodgkin's or
non-Hodgkin's Lymphoma:

- Group A:

- with active disease.

- in second or subsequent relapse

- in first relapse for indolent lymphoma after first line therapy for relapse

- or first relapse if immunosuppressive chemotherapy contraindicated.

- primary refractory disease or if persistent disease after first line
therapy of relapse.

- or multiply relapsed patients in remission who are at a high risk of relapse

- or the Lymphoma is a second malignancy e.g. a Richters transformation of CLL
after failing frontline therapy

OR

- Group B: After autologous or syngeneic SCT (as adjuvant therapy)

2. Life expectancy of 6 weeks or greater.

3. Hgb greater than 8.0

4. Patient, parent/guardian able to give informed consent.

Inclusion Criteria:

TREATMENT:

1. Any patient, at least 18 yrs old regardless of sex, with a diagnosis of Hodgkin's or
non-Hodgkin's Lymphoma:

Group A:

- with active disease

- in second or subsequent relapse

- in first relapse for indolent lymphoma after first line therapy for relapse

- or first relapse if immunosuppressive chemotherapy contraindicated

- primary refractory disease or if persistent disease after first line
therapy of relapse

- or multiply relapsed patients in remission who are at a high risk of relapse)

- or the Lymphoma is a second malignancy e.g. a Richters transformation of CLL
after failing front line therapy.

OR

- Group B: After autologous or syngeneic SCT (as adjuvant therapy)

2. Life expectancy of 6 weeks or greater.

3. Karnofsky/Lansky score of 50 or greater.

4. Bilirubin 2x or less of upper limit of normal, AST 3x or less than the upper limit of
normal, and Hgb >8.0

5. Creatinine 2x or less of upper limit of normal for age.

6. Patients should have been off other investigational therapy for one month prior to
entry in this study.

7. Patients should have been off conventional therapy for at least 1 week prior to entry
in this study

8. Patient able to give informed consent.

9. Due to unknown effects of this therapy on a fetus, pregnant women are excluded from
this research. The male partner should use a condom Females of child-bearing
potential should use of at least two forms of contraception unless female has had a
hysterectomy or tubal ligation.

Exclusion Criteria:

PROCUREMENT:

1. Patients with severe intercurrent infection.

2. Donors who are HIV positive at time of procurement. (test can be pending)

TREATMENT:

1. Patients with severe intercurrent infection.

2. Patients receiving systemic corticosteroids.

3. Pregnant.